Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase Full Text
Diabetes Care, 09/28/2011
Clinical Article
Bergenstal RM et al. – Switching from optimized multiple daily injection (MDI) to sensor–augmented pump (SAP) therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
Methods- The 6–month, single–crossover continuation phase of Sensor–Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1–year randomized study.
- The primary outcome was change in A1C in the crossover group.
- A1C values were initially lower in the continuing–SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001).
- A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05).
